Bifogade filer
NET ASSET VALUE – 31 May 2026
Kurs
0,00%
Prenumeration
Kalender
| Est. tid* | ||
| 2027-01-20 | 08:00 | Bokslutskommuniké 2026 |
| 2026-10-15 | 08:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-09 | 08:00 | Kvartalsrapport 2026-Q2 |
| 2026-06-15 | N/A | Extra Bolagsstämma 2026 |
| 2026-04-15 | - | Kvartalsrapport 2026-Q1 |
| 2026-03-27 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2026-03-26 | - | Årsstämma |
| 2026-01-21 | - | Bokslutskommuniké 2025 |
| 2025-10-22 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-31 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2025-05-14 | - | Årsstämma |
| 2025-04-16 | - | Kvartalsrapport 2025-Q1 |
| 2025-01-22 | - | Bokslutskommuniké 2024 |
| 2024-10-16 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-17 | - | Kvartalsrapport 2024-Q2 |
| 2024-07-12 | - | Split FLERIE 100:1 |
| 2024-05-14 | - | Årsstämma |
| 2024-05-08 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2024-04-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-24 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-08 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2022-06-01 | - | Årsstämma |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-04 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2021-06-03 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2021-01-12 | - | Extra Bolagsstämma 2020 |
| 2020-11-25 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-21 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2020-04-20 | - | Årsstämma |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Kvartalsrapport 2019-Q3 |
| 2019-10-09 | - | Extra Bolagsstämma 2019 |
| 2019-08-15 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-07 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2019-05-06 | - | Årsstämma |
| 2019-05-06 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-19 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-26 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | X-dag ordinarie utdelning FLERIE 0.00 SEK |
| 2017-05-30 | - | Årsstämma |
| 2017-05-30 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-22 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
On the 31 May 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,466 million and NAV per share was SEK 36.44. Return on NAV* in the month was -0.34%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 3.66 | 10.0% |
| Prokarium | 50% | 277 | 2.91 | 8.0% |
| Empros Pharma | 79% | 204 | 2.15 | 5.9% |
| KAHR Medical | 34% | 199 | 2.09 | 5.7% |
| Xspray Pharma | 17% | 198 | 2.08 | 5.7% |
| Atrogi | 44% | 197 | 2.07 | 5.7% |
| Bonsai Biotherapeutics | 100% | 158 | 1.66 | 4.6% |
| Microbiotica | 10% | 124 | 1.31 | 3.6% |
| Xintela | 60% | 110 | 1.16 | 3.2% |
| AnaCardio | 13% | 79 | 0.83 | 2.3% |
| Mendus | 23% | 75 | 0.79 | 2.2% |
| Geneos Therapeutics | 12% | 66 | 0.70 | 1.9% |
| EpiEndo Pharmaceuticals | 9% | 53 | 0.56 | 1.5% |
| Vitara Biomedical | 11% | 52 | 0.55 | 1.5% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.35 | 1.0% |
| Egetis Therapeutics | 1% | 29 | 0.30 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.11 | 0.3% |
| Strike Pharma | 18% | 11 | 0.11 | 0.3% |
| Total | 2,225 | 23.40 | 64.2% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.15 | 5.9% |
| NorthX Biologics | 61% | 202 | 2.12 | 5.8% |
| Chromafora | 28% | 137 | 1.45 | 4.0% |
| Nanologica | 50% | 104 | 1.09 | 3.0% |
| Frontier Biosolutions | 2% | 26 | 0.27 | 0.7% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 673 | 7.08 | 19.4% | |
| Assets related to Portfolio companies | 211 | 2.22 | 6.1% | |
| Other assets and liabilities | 356 | 3.74 | 10.3% | |
| Net Asset Value | 3,466 | 36.44 | 100.0% | |
* Following the bonus issue of 11,888,785 shares conducted in May, which will be followed by a cancellation of 8,412,578 shares to be approved in June, the return for the month is calculated on total NAV instead of as previously NAV per share.
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE – 31 May 2026